ResMed Keeps Bull Amid Weight-Loss Drug Trials -- Market Talk

Dow Jones04-19

0123 GMT - Breathing-tech manufacturer ResMed keeps its bull at Jarden following drugmaker Eli Lilly's weight-loss drug trial results that the investment advisor's analysts say were largely as anticipated. A pair of late-stage studies showed Eli Lilly's weight-loss drug significantly reduced the severity of sleep apnea in obese adults, but the Jarden analysts say it is important to recognize that the trials were not a head-to-head contest with devices such as those sold by ResMed. They say that so-called CPAP machines remain the gold-standard for obstructive sleep-apnea treatment. Jarden keeps an overweight rating and A$31.33 target price on ResMed's Australia-listed securities, which are up 1.0% at A$27.91. (stuart.condie@wsj.com)

(END) Dow Jones Newswires

April 18, 2024 21:23 ET (01:23 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2428457516?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-19 09:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2428457516","market":"fut","top_or_hot":-1,"title":"ResMed Keeps Bull Amid Weight-Loss Drug Trials -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0123 GMT - Breathing-tech manufacturer ResMed keeps its bull at Jarden following drugmaker Eli Lilly's weight-loss drug trial results that the investment advisor's analysts say were largely as anticipated. A pair of late-stage studies showed Eli Lilly's weight-loss drug significantly reduced the severity of sleep apnea in obese adults, but the Jarden analysts say it is important to recognize that the trials were not a head-to-head contest with devices such as those sold by ResMed. They say that so-called CPAP machines remain the gold-standard for obstructive sleep-apnea treatment. Jarden keeps an overweight rating and A$31.33 target price on ResMed's Australia-listed securities, which are up 1.0% at A$27.91. (stuart.condie@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 18, 2024 21:23 ET (01:23 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ResMed Keeps Bull Amid Weight-Loss Drug Trials -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nResMed Keeps Bull Amid Weight-Loss Drug Trials -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-19 09:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>0123 GMT - Breathing-tech manufacturer ResMed keeps its bull at Jarden following drugmaker Eli Lilly's weight-loss drug trial results that the investment advisor's analysts say were largely as ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RMD","symbol_name":"瑞思迈","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2428457516","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2428457516","pubTimestamp":1713489780,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0123 GMT - Breathing-tech manufacturer ResMed keeps its bull at Jarden following drugmaker Eli Lilly's weight-loss drug trial results that the investment advisor's analysts say were largely as anticipated. A pair of late-stage studies showed Eli Lilly's weight-loss drug significantly reduced the severity of sleep apnea in obese adults, but the Jarden analysts say it is important to recognize that the trials were not a head-to-head contest with devices such as those sold by ResMed. They say that so-called CPAP machines remain the gold-standard for obstructive sleep-apnea treatment. Jarden keeps an overweight rating and A$31.33 target price on ResMed's Australia-listed securities, which are up 1.0% at A$27.91. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"RMD":"瑞思迈","RMD.AU":"Resmed DRC"},"translate_title":"ResMed在减肥药物试验中保持牛市——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RMD":1,"RMD.AU":0.9},"content_text":"0123 GMT - Breathing-tech manufacturer ResMed keeps its bull at Jarden following drugmaker Eli Lilly's weight-loss drug trial results that the investment advisor's analysts say were largely as anticipated. A pair of late-stage studies showed Eli Lilly's weight-loss drug significantly reduced the severity of sleep apnea in obese adults, but the Jarden analysts say it is important to recognize that the trials were not a head-to-head contest with devices such as those sold by ResMed. They say that so-called CPAP machines remain the gold-standard for obstructive sleep-apnea treatment. Jarden keeps an overweight rating and A$31.33 target price on ResMed's Australia-listed securities, which are up 1.0% at A$27.91. (stuart.condie@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 18, 2024 21:23 ET (01:23 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2428457516"}